Tragic Loss in Pfizer’s Duchenne Gene Therapy Trial Raises Concerns
$Pfizer(PFE.US$
Young participant in Pfizer’s Phase 2 DAYLIGHT trial passes away.
Study examines gene therapy for Duchenne muscular dystrophy.
Pfizer pauses dosing in related Phase 3 CIFFREO trial.
Company working with regulators to investigate the incident.
Other trial activities continue despite dosing pause.
Young participant in Pfizer’s Phase 2 DAYLIGHT trial passes away.
Study examines gene therapy for Duchenne muscular dystrophy.
Pfizer pauses dosing in related Phase 3 CIFFREO trial.
Company working with regulators to investigate the incident.
Other trial activities continue despite dosing pause.
Pfizer committed to transparency and ongoing communication.
Community expresses deep sorrow and calls for support
Community expresses deep sorrow and calls for support
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
